1. Andrew SM, Pimm MV, Perkins AC, Baldwin RW. Comparative imaging and biodistribution studies with anti-CEA monoclonal antibody and its F(ab)2 and Fab fragments in mice with colon carcinoma xenografts. Eur. J. Nucl. Med. 1986; 12: 168–173.
2. Arps H, Dietel M, Klapdor R, Kremer B. Immunohistologically determined expression of the tumor-associated antigents CA19-9, CA 125, 17-1A and CA 50 in tumors of the gastro-intestinai tract. In: Clinical Relevance of New Monoclonal A.ntibodies, 3rd Symposium on Tumor Markers, Hamburg 1985. Greten H, Klapdor R, eds., Stuttgart-New York, Georg Thieme Verlag, 1986; pp. 276–284.
3. Atkinson BF, Ernst CS, Herlyn M, Steplewski Z, Sears HF, Koprowski H. Gastrointestinal cancer-associated antigen in immunoperoxydase assay. Cancer Res. 1982;42: 4820–4823.
4. Baum RP, Lorenz M, Senekowitsch R, Albrecht M, Hör G. Klinische Ergebnisse der Immunszintigraphie und Radioimmuntherapie. Nucl. Med. 1987;26: 68–78.
5. Bertoglio F, Percivale P, Bartolomeo S, Schenone F, Meszaros P, Conzi GF, Spina B, Nicolo G, Spagnolo W, Badellino F. Radioimmunoguided surgery (RIGS-TM) for colorectal cancer with B72.3 125-I-monoclonal antibody. In: Recent Results in Tumor Diagnosis and Therapy, Klapdor R, ed., San Francisco, Zuckschwerdt, München Bern Wien, 1990; pp. 437–443.